3 Small Cap Biotechs With Upcoming Catalysts

Running an analysis on just the NSAI resistant patients we see a hazard ratio of 0.47, or a reduction in risk by 53% which is far more significant and more representative of the patients in the phase 3. The company also baked in an additional hedge by measuring for hyperactetylation (HA), which offers the possibility of approval in a subset of highly epigenetically modified patients -- PFS in HA+ patients was 8.55 months vs 2.76months in HA- in the ENCORE301 study.

The company has guided for a November update for data which is based upon the un-blinding which occurs at full enrolment. This interim look here may be enough to stop the trial for efficacy and possible approval, given that most approvals in this setting have been on PFS.

Also, there will be another ‘shot-on-goal’ so-to-speak with OS next year. Notably, OS in the broad phase 2 design showed a much more significant outcome of 28.13 months vs. 19.84 months in a single agent setting. Based upon the shots on goal, the tailoring of the trial to match the hypothesis, as well as the relatively low valuation in the sub $200M range, we find the risk reward favourable here heading into pending data.

Affimed (AFMD) has a rather important upcoming data sets in Q4. Our main focus is on the company’s Tcell engager, AFM 11. Our report is very in-depth, so it would take up way too many pages here to delve into. 

1 2 3
View single page >> |

Disclosure: We are long $BLRX, $AFMD, $SNDX. To read our free report on AFM 11, please use this ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Donald Kaplan 2 years ago Member's comment

Good data, thanks.